Summit Therapeutics Shares Drop 8% After $500M Offering to Fund Ivonescimab R&D
SMMT•Summit Therapeutics announced a $500M common stock offering (with a $75M overallotment option), sending shares down nearly 8% in pre-market trade. The company will use proceeds to advance R&D of ivonescimab, which a HARMONi-6 interim analysis showed cut death risk 34% versus tislelizumab with chemotherapy.
1. Offering Details
Summit Therapeutics launched a $500 million common stock offering, with underwriters granted a 30-day option to purchase up to an additional $75 million of shares, to raise capital for its pipeline.
2. Share Price Reaction
Shares fell nearly 8% in pre-market trading following the offering announcement, reflecting investor concerns over potential dilution and market sentiment.
3. Use of Proceeds
Net proceeds will primarily support continued research and development of ivonescimab, with remaining funds allocated to working capital and general corporate purposes.
4. Clinical Trial Results
A planned interim analysis of the HARMONi-6 study showed ivonescimab plus chemotherapy reduced the risk of death by 34% compared with tislelizumab plus chemotherapy, with 24-month overall survival rates of 64.7% versus 48.6%.
